Login Register Cart 0
Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

miRNA-633 and KAI1 as Potential Biomarkers of Malignant Melanoma with Gastric Cancer

Author(s): Zheng-Xiang Wang*, Guang-Jing Zhang, Xiu-Fang Yang, Shi-Jun Feng, Shan-Shan Ji and Ya-Bin Qi

Volume 26, Issue 5, 2023

Published on: 23 August, 2022

Page: [1001 - 1014] Pages: 14

DOI: 10.2174/1386207325666220616125608

Price: $65

Abstract

Objective: Malignant melanoma with gastric cancer is one of the most malignant tumors. However, there have been no reports on the effects of KAI1 and miRNA-633 on the survival and prognosis of patients with malignant melanoma with gastric cancer.

Methods: Fifty patients with malignant melanoma and gastric cancer were collected from October 2017 to December 2019. The clinical parameters included clinical information, such as sex, age, tumor size, and tumor staging. RT-qPCR was used to detect the expression of KAI1 and miRNA- 633. The role of KAI1 and miRNA-633 on the overall survival of melanoma was explored by the Pearson chi-square test, Spearman-rho correlation test, Univariate and multivariate cox regression analyses, and Kaplan–Meier method. Furthermore, the bioinformatic analysis was used to verify the role of KAI1 and miRNA-633 on malignant melanoma with gastric cancer.

Results: The expression of KAI1 and miRNA-633 was significantly related with the tumor size and staging of tumor (p<0.05) based on the Pearson chi-square test. Spearman’s correlation coefficient displayed that KAI1 was significantly correlated with the miRNA-633 (ρ=-0.439, p=0.001). The result of multivariate cox proportional regression analysis showed that KAI1 (HR =0.109, 95% CI: 0.031-0.375, p< 0.001), and miRNA-633 (HR = 13.315, 95% CI: 3.844-46.119, p<0.001) were significantly associated with overall survival.

Conclusion: The low expression level of KAI1 and high expression of miRNA-633 are significantly correlated with the poor overall survival prognosis of malignant melanoma with gastric cancer, to provide a basis for KAI1 and miRNA-633 to become novel molecular targets for malignant melanoma with gastric cancer.

Keywords: Melanoma, gastric cancer, KAI1, miRNA-633, potential biomarkers, regression, prognosis.

Next »
[1]
De Smedt, J.; Van Kelst, S.; Boecxstaens, V.; Stas, M.; Bogaerts, K.; Vanderschueren, D.; Aura, C.; Vandenberghe, K.; Lambrechts, D.; Wolter, P.; Bechter, O.; Nikkels, A.; Strobbe, T.; Emri, G.; Marasigan, V.; Garmyn, M. Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): A randomized controlled trial. BMC Cancer, 2017, 17(1), 562.
[http://dx.doi.org/10.1186/s12885-017-3538-4] [PMID: 28835228]
[2]
Jerant, A.F.; Johnson, J.T.; Sheridan, C.D.; Caffrey, T.J. Early detection and treatment of skin cancer. Am. Fam. Physician, 2000, 62(2), 357-368, 375-376, 381-382.
[PMID: 10929700]
[3]
Balch, C.M.; Gershenwald, J.E.; Soong, S.J.; Thompson, J.F.; Atkins, M.B.; Byrd, D.R.; Buzaid, A.C.; Cochran, A.J.; Coit, D.G.; Ding, S.; Eggermont, A.M.; Flaherty, K.T.; Gimotty, P.A.; Kirkwood, J.M.; McMasters, K.M.; Mihm, M.C., Jr; Morton, D.L.; Ross, M.I.; Sober, A.J.; Sondak, V.K. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol., 2009, 27(36), 6199-6206.
[http://dx.doi.org/10.1200/JCO.2009.23.4799] [PMID: 19917835]
[4]
Hernandez, B.Y.; Green, M.D.; Cassel, K.D.; Pobutsky, A.M.; Vu, V.; Wilkens, L.R. Preview of Hawaii cancer facts and figures 2010. Hawaii Med. J., 2010, 69(9), 223-224.
[PMID: 20848386]
[5]
Houghton, A.N.; Polsky, D. Focus on melanoma. Cancer Cell, 2002, 2(4), 275-278.
[http://dx.doi.org/10.1016/S1535-6108(02)00161-7] [PMID: 12398891]
[6]
KAI1 is a potential target for anti-metastasis in pancreatic cancer cells. World J. Gastroenterol., 2008, 14(7), 1126-1132.
[http://dx.doi.org/10.3748/wjg.14.1126]
[7]
Tang, Y.; Cheng, Y.; Martinka, M.; Ong, C.J.; Li, G. Prognostic significance of KAI1/CD82 in human melanoma and its role in cell migration and invasion through the regulation of ING4. Carcinogenesis, 2014, 35(1), 86-95.
[http://dx.doi.org/10.1093/carcin/bgt346] [PMID: 24130172]
[8]
Zhang, G.; Cheng, Y.; Chen, G.; Tang, Y.; Ardekani, G.; Rotte, A.; Martinka, M.; McElwee, K.; Xu, X.; Wang, Q.; Zhou, Y. Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis. Oncotarget, 2015, 6(26), 23026-23035.
[http://dx.doi.org/10.18632/oncotarget.4854] [PMID: 26246476]
[9]
Wang, Y.; Yang, R.; Wang, X.; Ci, H.; Zhou, L.; Zhu, B.; Wu, S.; Wang, D. Evaluation of the correlation of vasculogenic mimicry, Notch4, DLL4, and KAI1/CD82 in the prediction of metastasis and prognosis in non-small cell lung cancer. Medicine (Baltimore), 2018, 97(52), e13817.
[http://dx.doi.org/10.1097/MD.0000000000013817] [PMID: 30593175]
[10]
Lee, M.S.; Lee, J.; Kim, Y.M.; Lee, H. The metastasis suppressor CD82/KAI1 represses the TGF-β (1) and Wnt signalings inducing epithelial-to-mesenchymal transition linked to invasiveness of prostate cancer cells. Prostate, 2019, 79(12), 1400-1411.
[PMID: 31212375]
[11]
Mohr, A.M.; Mott, J.L. Overview of microRNA biology. Semin. Liver Dis., 2015, 35(1), 3-11.
[http://dx.doi.org/10.1055/s-0034-1397344] [PMID: 25632930]
[12]
Zhang, T.; Wu, Y.C.; Mullane, P.; Ji, Y.J.; Liu, H.; He, L.; Arora, A.; Hwang, H.Y.; Alessi, A.F.; Niaki, A.G.; Periz, G.; Guo, L.; Wang, H.; Elkayam, E.; Joshua-Tor, L.; Myong, S.; Kim, J.K.; Shorter, J.; Ong, S.E.; Leung, A.K.L.; Wang, J. FUS regulates activity of microRNA-mediated gene silencing. Mol. Cell, 2018, 69(5), 787-801.e8.
[http://dx.doi.org/10.1016/j.molcel.2018.02.001] [PMID: 29499134]
[13]
Abbas, O.; Miller, D.D.; Bhawan, J. Cutaneous malignant melanoma: Update on diagnostic and prognostic biomarkers. Am. J. Dermatopathol., 2014, 36(5), 363-379.
[http://dx.doi.org/10.1097/DAD.0b013e31828a2ec5] [PMID: 24803061]
[14]
Haase-Kohn, C.; Laube, M.; Donat, C.K.; Belter, B.; Pietzsch, J. CRISPR/Cas9 mediated knockout of cyclooxygenase-2 gene inhibits invasiveness in A2058 melanoma cells. Cells, 2022, 11(4), 749.
[http://dx.doi.org/10.3390/cells11040749] [PMID: 35203404]
[15]
Bao, Y.; Cui, J.; Yue, Y.; Cao, S.; Li, X.; Liu, L. ERBB3 binding protein 1 promotes the progression of malignant melanoma through activation of the Wnt/β-catenin signaling pathway. Cancer Cell Int., 2022, 22(1), 44.
[http://dx.doi.org/10.1186/s12935-022-02473-6] [PMID: 35093077]
[16]
Cummins, D.L.; Cummins, J.M.; Pantle, H.; Silverman, M.A.; Leonard, A.L.; Chanmugam, A. Cutaneous malignant melanoma. Mayo Clin. Proc., 2006, 81(4), 500-507.
[http://dx.doi.org/10.4065/81.4.500] [PMID: 16610570]
[17]
Ombra, M.N.; Paliogiannis, P.; Stucci, L.S.; Colombino, M.; Casula, M.; Sini, M.C.; Manca, A.; Palomba, G.; Stanganelli, I.; Mandalà, M.; Gandini, S.; Lissia, A.; Doneddu, V.; Cossu, A.; Palmieri, G. Dietary compounds and cutaneous malignant melanoma: Recent advances from a biological perspective. Nutr. Metab. (Lond.), 2019, 16, 33.
[http://dx.doi.org/10.1186/s12986-019-0365-4] [PMID: 31139235]
[18]
Zhang, B.H.; Liu, W.; Li, L.; Lu, J.G.; Sun, Y.N.; Jin, D.J.; Xu, X.Y. KAI1/CD82 and MRP1/CD9 serve as markers of infiltration, metastasis, and prognosis in laryngeal squamous cell carcinomas. Asian Pac. J. Cancer Prev., 2013, 14(6), 3521-3526.
[http://dx.doi.org/10.7314/APJCP.2013.14.6.3521] [PMID: 23886139]
[19]
Woo, L.J.; Jin, H.; Wook, K.Y.; Whan, C.C.; Il, C.J.; Injoo, H.; Yeon, Y.J.; Jin, K. Eun, C.Y.; Hyun, K.Y.; Eun, L.S.; Cheol, L.; Hyun, J.D.; Heeyoung, S.; Seung, C.B.; Hee, B.S.; Soo, K.H. KAI1(CD82) is a key molecule to control angiogenesis and switch angiogenic milieu to quiescent state. J. Hematol. Oncol., 2021, 14(1)
[20]
Liu, W.M.; Zhang, X.A. KAI1/CD82, a tumor metastasis suppressor. Cancer Lett., 2006, 240(2), 183-194.
[http://dx.doi.org/10.1016/j.canlet.2005.08.018] [PMID: 16260083]
[21]
Bandyopadhyay, S.; Zhan, R.; Chaudhuri, A.; Watabe, M.; Pai, S.K.; Hirota, S.; Hosobe, S.; Tsukada, T.; Miura, K.; Takano, Y.; Saito, K.; Pauza, M.E.; Hayashi, S.; Wang, Y.; Mohinta, S.; Mashimo, T.; Iiizumi, M.; Furuta, E.; Watabe, K. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat. Med., 2006, 12(8), 933-938.
[http://dx.doi.org/10.1038/nm1444] [PMID: 16862154]
[22]
Ichikawa, T.; Ichikawa, Y.; Dong, J.; Hawkins, A.L.; Griffin, C.A.; Isaacs, W.B.; Oshimura, M.; Barrett, J.C.; Isaacs, J.T. Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res., 1992, 52(12), 3486-3490.
[PMID: 1596907]
[23]
Stipp, C.S.; Kolesnikova, T.V.; Hemler, M.E. Functional domains in tetraspanin proteins. Trends Biochem. Sci., 2003, 28(2), 106-112.
[http://dx.doi.org/10.1016/S0968-0004(02)00014-2] [PMID: 12575999]
[24]
Son, B.H.; Choi, J.S.; Lee, J.H. Prognostic values of KAI1 and survivin expression in an infiltrating ductal carcinoma of the breast. Pathology, 2005, 37(2), 131-136.
[http://dx.doi.org/10.1080/00313020500058144] [PMID: 16028840]
[25]
Stark, A.M.; Tongers, K.; Maass, N.; Mehdorn, H.M.; Held-Feindt, J. Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J. Cancer Res. Clin. Oncol., 2005, 131(3), 191-198.
[http://dx.doi.org/10.1007/s00432-004-0629-9] [PMID: 15592684]
[26]
Malik, F.A.; Sanders, A.J.; Jiang, W.G. KAI-1/CD82, the molecule and clinical implication in cancer and cancer metastasis. Histol. Histopathol., 2009, 24(4), 519-530.
[PMID: 19224455]
[27]
Hemler, M.E. Specific tetraspanin functions. J. Cell Biol., 2001, 155(7), 1103-1107.
[http://dx.doi.org/10.1083/jcb.200108061] [PMID: 11756464]
[28]
Kim, J.H.; Kim, B.; Cai, L.; Choi, H.J.; Ohgi, K.A.; Tran, C.; Chen, C.; Chung, C.H.; Huber, O.; Rose, D.W.; Sawyers, C.L.; Rosenfeld, M.G.; Baek, S.H. Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature, 2005, 434(7035), 921-926.
[http://dx.doi.org/10.1038/nature03452] [PMID: 15829968]
[29]
Guo, C.; Liu, Q.G.; Zhang, L.; Song, T.; Yang, X. Expression and clinical significance of p53, JunB and KAI1/CD82 in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int., 2009, 8(4), 389-396.
[PMID: 19666408]
[30]
Marsetti, P.S.; Milagro, F.I.; Zulet, M.Á.; Martínez, J.A.; Lorente-Cebrián, S. Changes in miRNA expression with two weight-loss dietary strategies in a population with metabolic syndrome. Nutrition, 2021, 83, 111085.
[http://dx.doi.org/10.1016/j.nut.2020.111085] [PMID: 33418490]
[31]
Liu, H.; Yin, J.; Wang, H.; Jiang, G.; Deng, M.; Zhang, G.; Bu, X.; Cai, S.; Du, J.; He, Z. FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Cell. Signal., 2015, 27(3), 510-518.
[http://dx.doi.org/10.1016/j.cellsig.2015.01.001] [PMID: 25578861]
[32]
Zhen, Y.; Ye, Y.; Wang, H.; Xia, Z.; Wang, B.; Yi, W.; Deng, X. Knockdown of SNHG8 repressed the growth, migration, and invasion of colorectal cancer cells by directly sponging with miR-663. Biomed. Pharmacother., 2019, 116, 109000.
[http://dx.doi.org/10.1016/j.biopha.2019.109000] [PMID: 31152930]
[33]
Wang, Z.; Zhang, H.; Zhang, P.; Dong, W.; He, L. MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma. Tumour Biol., 2016, 37(6), 7633-7644.
[http://dx.doi.org/10.1007/s13277-015-4653-y] [PMID: 26687649]
[34]
Liang, S.; Zhang, N.; Deng, Y.; Chen, L.; Zhang, Y.; Zheng, Z.; Luo, W.; Lv, Z.; Li, S.; Xun, T. Increased serum level of MicroRNA-663 is correlated with poor prognosis of patients with nasopharyngeal carcinoma. Dis. Markers, 2016, 2016, 7648215.
[PMID: 27667893]

Rights & Permissions Print Cite
Article Metrics
30
3
© 2024 Bentham Science Publishers | Privacy Policy